PI3K and MAPK inhibitor combination therapies should include solid tumors that depend on MAPK pathway activation, such as BRAF-mutant and KRAS-mutant melanoma, colorectal carcinoma and ovarian cancer.226–228. The gene discussed is PIK3CD; the disease is ovarian carcinoma.